QualityStocks News - Avant Diagnostics (AVDX) Begins OvaDx® Ovarian Cancer Test Calibration Necessary for FDA Submission

QualityStocks would like to highlight Avant Diagnostics, Inc. (OTCQB: AVDX), a medical diagnostic technology company that specializes in large panel biomarker screening. The company's first test, OvaDx®, is a sophisticated microarray-based test designed to detect pre-symptomatic ovarian cancer by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.

In the company’s news,

Avant Diagnostics, an innovator in molecular diagnostics, this morning announced the start of calibration testing in preparation for the company’s validation study of OvaDx®, which will be used to support a pre-submission package to the United States Food and Drug Administration (“FDA”). Avant expects to complete the calibration testing within 30 days.

OvaDx® is a sophisticated microarray-based test proposed for use in monitoring women previously diagnosed with ovarian cancer. Pre-clinical research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer.

Upon completion of the testing, Avant said it intends to test the previously purchased set of ovarian cancer specimens, including serial sets obtained from women previously diagnosed with ovarian cancer, which will serve as the validation study and form the basis of the pre-submission package that will be submitted to FDA for review and comment prior to the commencement of the OvaDx® 510(k) trial.

The validation study and 510(k) trial will be conducted in a double-blinded environment supervised by independent clinical research organization DOCRO, Inc. Validation study results are expected to be published in a peer-reviewed scientific journal within six months of test completion and data analysis.

“The entire Avant team has been working tirelessly over the past few months to reach this critical milestone. We look forward to communicating to our shareholders and the markets as we move through the FDA negotiations and review of our 510(k) submission,” Gregg Linn, Avant’s CEO and president stated in the news release.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net  

To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage

To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks

Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net   

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.